Søgning på udtrykket 'rsv' giver 44 resultater


Kalender [2] Nyt fra tidsskrifterne [+20] Aktuelle smitsomme sygdomme [+20]

…er som følger: 1) Det vises for første gang, at et medikament kan reaktivere latent HIV-virus under samtidig HAART-behandling i en grad, så virus kan påvises i perifert blod. 2) Der er (omend videnskaligt svage) indicier på, at HIV-reservoir kan reduceres hos nogle patienter, og at effekten af det innate immunforsvar er af betydning herfor. 3) Det er den første originalartikel trykt i den allerførste udgave af et helt nyt HIV-tidsskrift (som formentlig vil blive et betydende tidsskrift på området).

…n (per oralt) blev undersøgt på ca. 700 Vietnamesiske patienter. Men der kunne desværre ikke erkendes nogen forskel i de to grupper. I en leder i samme nummer af NEJM henleder Peter Donald opmærksomheden på de gode behandlingsresultater man har i Cape Town med et kun 6 måneders regime som inkluderer Ethionamid (Trecator), Isoniazid, Rifamipcin og Pyrazinamid. Hvem har herefter opskriften på et nyt, etisk forsvarligt, klinisk studie til behandling af en af de mest alvorlige neuroinfektioner vi kender?


Kalender [2]

14. maj, Auditorium 3 og 4, Hvidovre Hospital
24. august 2023, Emil Aarestrup Auditorium, Odense Universitetshospital

Nyt fra tidsskrifterne [+20]

Der er mere end 20 resultater, måske du vil se flere resultater her?
Clinical Infectious Diseases
6.06.2024
Abstract . Background . Data on the true prevalence of RSV among medically-attended acute respiratory illnesses (MAARI) has been limited by the lack of regular clinical testing of mild to moderate illnesses. Here we present a prospective evaluation of the epidemiology of RSV-associated MAARI across age groups and multimorbidity status over three seasons, which is informative in light of the recommendations for shared decision-making for vaccination in older adults.Methods . Ambulatory patients ≥6 months o…
Lancet Infectious Diseases
25.05.2024
Ad26.RSV.preF–RSV preF protein maintained high efficacy against RSV LRTD in older adults across three RSV seasons.
Lancet Microbe
16.05.2024
With recent studies showing nirsevimab infant immunisation significantly reduced respiratory syncytial virus (RSV)-related hospital admissions, and a maternal vaccine associated with significantly fewer RSV infections in infants, the outlook for RSV prevention in children is encouraging.
Journal of the American Medical Association
10.05.2024
A vaccine given during pregnancy that prevents respiratory syncytial virus (RSV) in infants was about 66% effective at protecting against RSV-associated respiratory illness, and about 69% effective at protecting against severe disease, according to a study in the New England Journal of Medicine. The data came from a randomized clinical trial involving more than 5000 pregnant people and their infants in 24 countries.
The Lancet Microbe
8.05.2024
With recent studies showing nirsevimab infant immunisation significantly reduced respiratory syncytial virus (RSV)-related hospital admissions, and a maternal vaccine associated with significantly fewer RSV infections in infants, the outlook for RSV prevention in children is encouraging.
Journal of Infectious Diseases
20.04.2024
Abstract . Respiratory syncytial virus (RSV) causes severe infections in infants, immunocompromised or elderly individuals resulting in annual epidemics of respiratory disease. Currently, limited clinical surveillance and the lack of predictable seasonal dynamics limits the public health response. Wastewater-based epidemiology (WBE) has recently been used globally as a key metric in determining prevalence of SARS-CoV-2 in the community but its application to other respiratory viruses is limited. In this stu…
BMC Infectious Diseases
12.04.2024
. Abstract. . Background. Respiratory syncytial virus (RSV) infection in children under 5 years have a significant clinical burden, also in primary care settings. This study investigates the epidemiology and burden of RSV in Italian children during the 2019/20 pre-pandemic winter season. . . . Methods. A prospective cohort study was conducte…
Journal of Medical Virology
2.04.2024
Journal of Medical Virology, Volume 96, Issue 4, April 2024.
Clinical Microbiology and Infection
15.03.2024
Each winter season, approximately 30% of infants younger than 1 year develop lower respiratory tract infections (LRTI), with the respiratory syncytial virus (RSV) the pathogen most frequently involved (1). As the main cause of hospitalization in infants and young children worldwide, LRTI disrupts health-care systems substantially (2).
New England Journal of Medicine
14.03.2024
New England Journal of Medicine, Volume 390, Issue 11, Page 1009-1021, March 2024.
New England Journal of Medicine
14.03.2024
New England Journal of Medicine, Volume 390, Issue 11, Page 1050-1051, March 2024.
Journal of Infectious Diseases
23.02.2024
Abstract . Background . An mRNA-based RSV vaccine, mRNA-1345, is under clinical investigation to address RSV disease burden in older adults.Methods . This phase 1, randomized, observer-blind, placebo-controlled, dose-ranging study evaluated safety, reactogenicity, and immunogenicity of mRNA-1345 in adults 65-79 years (NCT04528719). Participants were randomized to receive 1-dose of mRNA-1345 (12.5, 25, 50, 100, or 200-µg) or placebo and matched mRNA-1345 booster or placebo at 12-months.Results . Overall, 29…
Journal of Medical Virology
21.02.2024
Journal of Medical Virology, Volume 96, Issue 2, February 2024.
Journal of Infectious Diseases
2.02.2024
Abstract . Background . Respiratory syncytial virus (RSV) presents a global health concern. A lipid nanoparticle-encapsulated mRNA-based RSV vaccine (mRNA-1345) encoding the membrane-anchored RSV prefusion stabilised F glycoprotein (preF) is under clinical investigation.Methods . This phase 1, randomized, observer-blind, placebo-controlled dose escalation study assessed safety and immunogenicity of mRNA-1345 in healthy adults aged 18-49 years (NCT04528719). Participants were randomized to receive one dose o…
BMC Infectious Diseases
31.01.2024
. Abstract. . Background. Influenza and RSV coinfections are not commonly seen but are concerning as they can lead to serious illness and adverse clinical outcomes among vulnerable populations. Here we describe the clinical features and outcomes of influenza and RSV coinfections in hospitalized adults. . . . Methods. A cohort study was perfo…
Clinical Infectious Diseases
22.01.2024
Abstract . Background . The adjuvanted RSV prefusion F protein-based vaccine (RSVPreF3 OA) was efficacious against RSV-related lower respiratory tract disease (RSV-LRTD) in ≥60-year-olds over 1 RSV season. We evaluated efficacy and safety of 1 RSVPreF3 OA dose and of 2 RSVPreF3 OA doses given 1 year apart against RSV-LRTD over 2 RSV seasons post-dose 1.Methods . In this phase 3, blinded trial, ≥60-year-olds were randomized (1:1) to receive RSVPreF3 OA or placebo pre-season 1. RSVPreF3 OA recipients were…
Clinical Infectious Diseases
4.01.2024
Swedish Research Council10.13039/501100004359
New England Journal of Medicine
14.12.2023
New England Journal of Medicine, Volume 389, Issue 24, Page 2233-2244, December 2023.

Aktuelle smitsomme sygdomme [+20]

Der er mere end 20 resultater, måske du vil se flere resultater her?
Medscape Infectious Diseases
4.06.2024
For the first time, an mRNA vaccine has been approved for an indication other than COVID-19. The vaccine will join a couple other immunizations currently on the market for respiratory syncytial virus. . Medscape Medical News
Medscape Infectious Diseases
16.05.2024
Data raise questions about whether more testing for RSV and more vaccination are needed. . Medscape Medical News
Medscape Infectious Diseases
19.04.2024
Last year saw more than 50 new drug approvals, many of which may help internists better manage several common conditions in their patients. . Medscape Medical News
Eurosurveillance latest updates
12.04.2024
…ropean Mortality Monitoring Network (EuroMOMO) has observed excess mortality in Europe. During weeks 48 2023–6 2024, preliminary results show a substantially increased rate of 95.3 (95% CI:  91.7–98.9) excess all-cause deaths per 100,000 person-years for all ages. This excess mortality is seen in adults aged 45 years and older, and coincides with widespread presence of COVID-19, influenza and respiratory syncytial virus (RSV) observed in many European countries during the 2023/24 winter season. .
Medscape Infectious Diseases
10.04.2024
Pfizer said on Tuesday its respiratory syncytial virus (RSV) vaccine Abrysvo was well tolerated and generated an immune response in higher risk adults under the age of 60. . Reuters Health Information
Eurosurveillance latest updates
29.03.2024
. Background. Non-pharmaceutical interventions (NPIs) during the COVID-19 pandemic affected respiratory syncytial virus (RSV) circulation worldwide. . . Aim. To describe, for children aged 
Medscape Infectious Diseases
20.03.2024
Adult RSV infection can have serious consequences. These five things to know will help you recognize and protect the adult populations most vulnerable to severe disease. . Medscape Infectious Diseases
Medscape Infectious Diseases
14.03.2024
With a maternal vaccine already on the market to protect newborns from RSV, the outlook for another looked promising, but latest phase 3 trial of a new candidate is now halted over safety concerns. . Medscape Medical News
Medscape Infectious Diseases
8.03.2024
(Corrects typo in CDC agency's name in paragraph 1) . Reuters Health Information
Medscape Infectious Diseases
2.03.2024
Pfizer on Thursday said a single dose of its new respiratory syncytial virus (RSV) vaccine Abrysvo maintained its ability to protect against the illness through a second. . Reuters Health Information
Eurosurveillance latest updates
2.02.2024
. Background. There is currently no standardised approach to estimate respiratory syncytial virus (RSV) epidemics’ timing (or seasonality), a critical information for their effective prevention and control. . . Aim. We aimed to provide an overview of methods to define RSV seasonality and identify factors supporting method choice or interpretation/comparison of seasonal estimates. . . Methods. We systematically searched PubMed and Embase (2016–2021) for studies using quantitative approaches to dete…
Medscape Infectious Diseases
1.02.2024
Amid the current winter wave surge of respiratory virus cases, how challenging is it for physician's to distinguish between, diagnose, and treat COVID-19 vs RSV and influenza? . Medscape Medical News
Eurosurveillance latest updates
26.01.2024
After Luxembourg introduced nirsevimab immunisation against respiratory syncytial virus (RSV), estimated neonatal coverage was 84% (1,277 doses/1,524 births) in 2023. That year, paediatric RSV-related hospitalisations, especially concerning infants 
Medscape Infectious Diseases
6.12.2023
COVID-19 appears to be heading for a holiday season increase across most of the United States. . WebMD Health News
Medscape Infectious Diseases
12.11.2023
Despite our prevention efforts, some unlucky few may contract not just one of these viruses, but two at once or in close succession during the winter season. . WebMD Health News
Medscape Infectious Diseases
13.10.2023
The maternal RSV vaccine will significantly reduce infant hospitalizations and curb medical costs, finds a new modeling study exploring the benefit of widespread use. . Medscape Medical News
Medscape Infectious Diseases
12.10.2023
Wastewater monitoring is an established tool for tracking COVID, and now new evidence shows it can be used alongside clinical testing to assess the burden of influenza and RSV in communities. . Medscape Medical News
Morbidity and Mortality Weekly Report (MMWR)
6.10.2023
This report describes characteristics and outcomes of older adults hospitalized with respiratory syncytial virus.
Medscape Infectious Diseases
14.09.2023
The 2024 update of the CPT codes also adds what are meant to be consumer-friendly descriptors in Spanish. . Medscape Medical News

DSI på

Følg os på linkedin.com/company/dansk-selskab-for-infektionsmedicin

Nyhedsbrev

Skriv din email adresse og modtag nyheder om hjemmesiden.


© 2024 Dansk Selskab for Infektionsmedicin

CVR: 33634307

infmed.dk
Version: 2.14.1
PHP version: 8.0.30
Design: Christian Philip Fischer
Side indlæst på 0.893 s

Cookies og privatliv